Results 281 to 290 of about 159,964 (350)

Precision oncology in biliary tract cancer: the emerging role of liquid biopsy. [PDF]

ESMO Open
de Scordilli M, Bortolot M, Torresan S, Noto C, Rota S, Di Nardo P, Fumagalli A, Guardascione M, Ongaro E, Foltran L, Puglisi F.   +10 more
europepmc   +1 more source

Scheduled Inside Plastic Stent Exchange Prevents Cholangitis and Reduces Unplanned Hospitalization in Patients With Unresectable Malignant Hilar Biliary Obstruction

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives To prevent cholangitis in patients with unresectable malignant hilar biliary obstruction (MHBO), we recently implemented scheduled inside plastic stent (IS) exchange every 2–4 months. This study aimed to evaluate whether this strategy prevents cholangitis onset and reduces unplanned hospitalizations without increasing adverse events.
Joji Muramatsu, Kazuma Ishikawa, Norito Suzuki, Tomohiro Kubo, Makoto Yoshida, Ginji Omori, Ryo Ito, Shogo Miura, Kohichi Takada   +8 more
wiley   +1 more source

Efficacy and Toxicity Profile of Carboplatin/Gemcitabine Chemotherapy in Locally Advanced or Metastatic Biliary Tract Cancer: A Single UK Centre Experience. [PDF]

Cancers (Basel)
Baraka B, Ponda DJ, Hanna J, Gomez D, Aithal G, Arora A.   +5 more
europepmc   +1 more source

Supplementary Table S6 from A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy

Junji Furuse, Masafumi Ikeda, Makoto Ueno, Masayuki Furukawa, Chigusa Morizane, Tetsuo Takehara, Tomohiro Nishina, Akiko Todaka, Naohiro Okano, Kazuo Hara, Yousuke Nakai, Kazuyoshi Ohkawa, Takashi Sasaki, Kazuya Sugimori, Naoyuki Yokoyama, Kouji Yamamoto   +15 more
openalex   +1 more source

Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. [PDF]

Oncologist
Huang WK, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ, Chen SC, Yeh CN, Chen JS, Chen MH, Hsieh CH, Chou WC.   +12 more
europepmc   +1 more source

Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer. [PDF]

Front Public Health
Xie Y, Liu Q, Xiao S, Li X, Qiu L, Gu Y.
europepmc   +1 more source

Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Reimann P, Schneider EM, Djanani A, Mink S, Winder T, Benda M.   +5 more
europepmc   +1 more source

An emerging and promising anticancer strategy: colonization of engineered Staphylococcus epidermidis

MedComm
Yanyan Liu, Yulong Cai
doaj   +1 more source

SAR Studies around the SULT1A1-Activated Alkylator YC-1 as Cytotoxic Agents against Biliary Tract Cancer Cells. [PDF]

J Med Chem
Kong K, Zhao W, Shrimp JH, Vava M, Sinha R, Sharma S, Lee TD, Roth JS, Lee OW, Lewis D, Kearney SE, Rohde JM, Davis MI, Shah P, Wang AQ, Xu X, Shi L, Shen M, Boxer MB, Bardeesy N, Hall MD, Patnaik S.   +21 more
europepmc   +1 more source

DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment. [PDF]

Cancers (Basel)
Oda S, Kawakubo K, Kuwatani M, Tanaka S, Nakajima K, Shiratori S, Yonemura H, Nozawa S, Hirata K, Sugiura R, Sakamoto N.   +10 more
europepmc   +1 more source